If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

29 Aug 2022 14:17

Japan panel approves AstraZeneca's Evusheld COVID treatment

TOKYO, Aug 29 (Reuters) - Japan's health ministry said on Monday that its panel of experts had agreed to approve manufacturing and sales of AstraZeneca's COVID-19 preventive treatment Evusheld.

Read more
27 Aug 2022 16:19

AstraZeneca's Farxiga cuts death risk in heart failure patients -study

LONDON, Aug 27 (Reuters) - AstraZeneca's blockbuster diabetes drug Farxiga led to significant reductions in the risk of hospitalisation and death in people with all types of heart failure, according to study data released on Saturday, opening the door to a substantial increase in patients who could benefit.

Read more
26 Aug 2022 06:03

CORRECT: Japan approves Astra's Lynparza, Tagrisso, and Ultomiris

(Correcting the phase of the OlympiA trial.)

Read more
25 Aug 2022 15:43

ShoreCap stays at 'buy' for Astra Zeneca, citing prospects for earnings and sales growth, pipeline

(Sharecast News) - Analysts at ShoreCap doubled down on their recent reinitiation of coverage on AstraZeneca with a 'buy' recommendation, citing growth and pipeline prospects.

Read more
25 Aug 2022 08:57

TOP NEWS: Japan approves Astra's Lynparza, Tagrisso, and Ultomiris

(Alliance News) - AstraZeneca PLC on Thursday shared its latest regulatory successes in a key market, winning approvals for three treatments in Japan.

Read more
25 Aug 2022 08:05

AstraZeneca's Lynparza approved in Japan

(Sharecast News) - AstraZeneca and MSD's Lynparza has been approved in Japan for the treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence, the companies said on Thursday.

Read more
24 Aug 2022 08:00

TOP NEWS: AstraZeneca to present cancer drug data at oncology congress

(Alliance News) - AstraZeneca PLC on Wednesday announced it will provide new safety and efficacy data on several of its cancer drugs, purporting to show longer survival for cancer patients.

Read more
22 Aug 2022 11:04

IN BRIEF: Aptamer's annual revenue doubles on new contract wins

Aptamer Group PLC - York, England-based provider of custom services, diagnostics and therapeutics for biotechnology and pharmaceutical firms - For the year ended June 30, revenue is expected to more than double to GBP4.0 million from GBP1.6 million reported the prior 15-month period.

Read more
20 Aug 2022 17:01

Sector movers: Defensives knocking at technical resistance's door

(Sharecast News) - Interest rate sensitive segments of the FTSE 3500 dragged the index lower at the end of the week, as investors digested a flurry of Fed speakers overnight whose overarching message appeared to be that interest rates would remain higher for longer, although there were slight variations as to just how high.

Read more
19 Aug 2022 17:07

LONDON MARKET CLOSE: FTSE 100 keeps head above water as pound sinks

(Alliance News) - The FTSE 100 managed to outperform European counterparts on Friday due to weakness in the pound as consumer confidence in the UK fell to a record low, while attention turns to next week's Jackson Hole Symposium.

Read more
19 Aug 2022 12:06

LONDON MARKET MIDDAY: Weaker pound unable to keep FTSE in green

(Alliance News) - London's FTSE 100 outperformed peers but was unable to stave off selling pressure in a tough session for European stocks on Friday, despite sitting just above positive territory for much of the late-morning's trade.

Read more
17 Aug 2022 18:10

Sanofi trial failure halts work on breast cancer treatment amcenestrant

Aug 17 (Reuters) - Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.

Read more
16 Aug 2022 08:36

TOP NEWS: AstraZeneca's Lynparza wins FDA priority review in US

(Alliance News) - AstraZeneca PLC on Tuesday said its prostate cancer drug candidate Lynparza has received priority review from the US Food & Drug Administration.

Read more
16 Aug 2022 08:07

AstraZeneca's prostate cancer drug gets US priority review

(Sharecast News) - Pharmaceutical company AstraZeneca said its Lynparza prostate cancer treatment application had been granted priority review in the US.

Read more
15 Aug 2022 22:17

UK first to approve Omicron COVID shot with Moderna nod

LONDON, Aug 15 (Reuters) - Britain, the first country to approve a coronavirus vaccine in late 2020, has now also given the first green light to a variant-adapted shot that targets both the original and Omicron version of the virus.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.